Wave Life Sciences Ltd (WVE) - Net Assets
Based on the latest financial reports, Wave Life Sciences Ltd (WVE) has net assets worth $511.73 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($583.54 Million) and total liabilities ($71.81 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check WVE PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $511.73 Million |
| % of Total Assets | 87.69% |
| Annual Growth Rate | N/A |
| 5-Year Change | 1519.27% |
| 10-Year Change | 290.2% |
| Growth Volatility | 2239.43 |
Wave Life Sciences Ltd - Net Assets Trend (2013–2025)
This chart illustrates how Wave Life Sciences Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see WVE market cap overview.
Annual Net Assets for Wave Life Sciences Ltd (2013–2025)
The table below shows the annual net assets of Wave Life Sciences Ltd from 2013 to 2025. Also explore Wave Life Sciences Ltd (WVE) net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $526.23 Million | +151.17% |
| 2024-12-31 | $209.51 Million | +428.68% |
| 2023-12-31 | $39.63 Million | +187.89% |
| 2022-12-31 | $-45.09 Million | -238.75% |
| 2021-12-31 | $32.50 Million | -64.15% |
| 2020-12-31 | $90.65 Million | +26.60% |
| 2019-12-31 | $71.61 Million | -2.37% |
| 2018-12-31 | $73.35 Million | -47.54% |
| 2017-12-31 | $139.81 Million | +3.67% |
| 2016-12-31 | $134.86 Million | -12.14% |
| 2015-12-31 | $153.49 Million | +7472.32% |
| 2014-12-31 | $2.03 Million | +126.11% |
| 2013-12-31 | $-7.76 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Wave Life Sciences Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 131558900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.62 Billion | 307.18% |
| Other Comprehensive Income | $-250.00K | -0.05% |
| Other Components | $236.24 Million | 44.89% |
| Total Equity | $526.23 Million | 100.00% |
Wave Life Sciences Ltd Competitors by Market Cap
The table below lists competitors of Wave Life Sciences Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jiangsu Changbao Steeltube Co Ltd
SHE:002478
|
$858.12 Million |
|
Ryerson Holding Corp
NYSE:RYI
|
$858.13 Million |
|
LiaonWellhope Agri-Tech Co Ltd
SHG:603609
|
$858.54 Million |
|
Fujian Furi Electronics Co Ltd
SHG:600203
|
$859.05 Million |
|
Camden National Corporation
NASDAQ:CAC
|
$857.91 Million |
|
Vaudoise Assurances Holding SA
SW:VAHN
|
$857.33 Million |
|
TeamViewer AG
F:TMV
|
$857.02 Million |
|
Ningbo Thermal Power Co Ltd
SHG:600982
|
$856.97 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Wave Life Sciences Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 209,515,000 to 526,231,000, a change of 316,716,000 (151.2%).
- Net loss of 204,378,000 reduced equity.
- New share issuances of 472,486,000 increased equity.
- Other comprehensive income increased equity by 12,000.
- Other factors increased equity by 48,596,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-204.38 Million | -38.84% |
| Share Issuances | $472.49 Million | +89.79% |
| Other Comprehensive Income | $12.00K | +0.0% |
| Other Changes | $48.60 Million | +9.23% |
| Total Change | $- | 151.17% |
Book Value vs Market Value Analysis
This analysis compares Wave Life Sciences Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.43x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $-2.18 | $4.46 | x |
| 2014-12-31 | $0.10 | $4.46 | x |
| 2015-12-31 | $7.12 | $4.46 | x |
| 2016-12-31 | $5.91 | $4.46 | x |
| 2017-12-31 | $5.27 | $4.46 | x |
| 2018-12-31 | $2.53 | $4.46 | x |
| 2019-12-31 | $2.11 | $4.46 | x |
| 2020-12-31 | $2.31 | $4.46 | x |
| 2021-12-31 | $0.63 | $4.46 | x |
| 2022-12-31 | $-0.57 | $4.46 | x |
| 2023-12-31 | $0.37 | $4.46 | x |
| 2024-12-31 | $1.52 | $4.46 | x |
| 2025-12-31 | $3.12 | $4.46 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Wave Life Sciences Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -38.84%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -478.33%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 1.21x
- Recent ROE (-38.84%) is above the historical average (-125.13%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.54 Million |
| 2014 | -257.97% | 0.00% | 0.00x | 1.45x | $-5.43 Million |
| 2015 | -12.51% | -12631.58% | 0.00x | 1.08x | $-34.55 Million |
| 2016 | -41.08% | -3730.71% | 0.01x | 1.22x | $-68.89 Million |
| 2017 | -72.98% | -2754.72% | 0.02x | 1.30x | $-116.02 Million |
| 2018 | -199.94% | -1017.43% | 0.05x | 4.03x | $-153.99 Million |
| 2019 | -270.42% | -1211.52% | 0.06x | 3.97x | $-200.80 Million |
| 2020 | -165.37% | -746.68% | 0.07x | 3.08x | $-158.98 Million |
| 2021 | -376.16% | -298.42% | 0.20x | 6.37x | $-125.49 Million |
| 2022 | 0.00% | -4434.72% | 0.02x | 0.00x | $-157.31 Million |
| 2023 | -145.12% | -50.76% | 0.41x | 6.94x | $-61.48 Million |
| 2024 | -46.30% | -89.57% | 0.31x | 1.68x | $-117.96 Million |
| 2025 | -38.84% | -478.33% | 0.07x | 1.21x | $-257.00 Million |
Industry Comparison
This section compares Wave Life Sciences Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $161,895,707
- Average return on equity (ROE) among peers: -42.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Wave Life Sciences Ltd (WVE) | $511.73 Million | 0.00% | 0.14x | $858.11 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $109.30 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $170.10 Million | -16.06% | 0.05x | $310.51 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-12.35 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.35 Billion |
| Arbutus Biopharma Corp (ABUS) | $38.29 Million | -30.60% | 0.11x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.31 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $199.76 Million | -82.32% | 0.11x | $4.61 Billion |
About Wave Life Sciences Ltd
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent diso… Read more